The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays

Article English OPEN
Tewari, Nilanjana ; Zaitoun, Abed M ; Arora, Arvind ; Madhusudan, Srinivasan ; Ilyas, Mohammad ; Lobo, Dileep N (2013)
  • Publisher: Springer Nature
  • Journal: BMC Cancer, volume 13, pages 436-436 (eissn: 1471-2407)
  • Related identifiers: doi: 10.1186/1471-2407-13-436, pmc: PMC3849604
  • Subject: Research Article | CD3 | Genetics | CD8 | Tumour-associated lymphocytes | Immunohistochemistry | Prognosis | Cancer Research | Oncology | Pancreatic ductal adenocarcinoma

Background\ud Tumour-associated lymphocytes (TALs) have been linked with good prognosis in several solid tumours. This study aimed to evaluate the prognostic significance of CD3, CD8 and CD20 positive lymphocytes in pancreatic ductal adenocarcinoma.\ud \ud Methods\ud After histological re-evaluation of the tumours of 81 patients who underwent surgical resection for exclusively pancreatic ductal adenocarcinoma, tissue micro-arrays (TMA) were constructed and immunohistochemistry was performed for CD3, CD8 and CD20. The number of lymphocytes within specific tumour compartments (i.e. stromal and intratumoural) was quantified. X-tile software (Yale School of Medicine, CT, USA) was used to stratify patients into 'high’ and 'low’ for each of the lymphocytes stained and their association with survival. Receiver operating curves (ROC) were constructed to evaluate the association between the TALs, alone and in combination, with clinicopathological features.\ud \ud Results\ud CD3 and CD8 positive lymphocytes were associated with grade of tumour differentiation. The presence of intratumoural CD3 positive cells was associated with improved survival (p = 0.028), and intratumoural and stromal CD3 in combination also correlated with improved survival (p = 0.043). When CD20 positive lymphocyte levels were high, survival improved (p = 0.029) and similar results were seen for CD20 in combination with intratumoural CD3 (p = 0.001) and stromal CD8 (p = 0.013).\ud \ud Conclusions\ud This study has shown a correlation between the presence of TALs and survival in pancreatic ductal adenocarcinoma.
  • References (33)
    33 references, page 1 of 4

    1. Maitra A, Hruban RH: Pancreatic cancer. Annu Rev Pathol 2008, 3:157-188.

    2. Saif MW: Pancreatic neoplasm in 2011: an update. JOP 2011, 12:316-321.

    3. Heinemann V, Haas M, Boeck S: Systemic treatment of advanced pancreatic cancer. Canc Treat Rev 2012, 38:843-853.

    4. Ying JE, Zhu LM, Liu BX: Developments in metastatic pancreatic cancer: is gemcitabine still the standard? World J Gastroenterol 2012, 18:736-745.

    5. Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, Hiraoka N: Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Canc 2013, 108:914-923.

    6. Droeser R, Zlobec I, Kilic E, Guth U, Heberer M, Spagnoli G, Oertli D, Tapia C: Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers. BMC Canc 2012, 12:134.

    7. Ahmed MA, Aleskandarany MA, Rakha EA, Moustafa RZ, Benhasouna A, Nolan C, Green AR, Ilyas M, Ellis IO: A CD44(-)/CD24(+) phenotype is a poor prognostic marker in early invasive breast cancer. Breast Canc Res Treat 2011, 133:979-995.

    8. Ahmed MA, Al-Attar A, Kim J, Watson NF, Scholefield JH, Durrant LG, Ilyas M: CD24 shows early upregulation and nuclear expression but is not a prognostic marker in colorectal cancer. J Clin Pathol 2009, 62:1117-1122.

    9. Clevers H, Alarcon B, Wileman T, Terhorst C: The T cell receptor/CD3 complex: a dynamic protein ensemble. Annu Rev Immunol 1988, 6:629-662.

    10. Moebius U, Kober G, Griscelli AL, Hercend T, Meuer SC: Expression of different CD8 isoforms on distinct human lymphocyte subpopulations. Eur J Immunol 1991, 21:1793-1800.

  • Metrics
    No metrics available
Share - Bookmark